VARSOVIA, Polonia–(BUSINESS WIRE)–Polpharma Biologics Group anuncia que su empresa en participación con la empresa Santo Holding (Strüngmann Group), Bioeq, ha finalizado una colaboración comercial con Teva Pharmaceutical Industries Ltd. para el candi…
Author: Business Wire
Two Prominent Optometric Practices Partner with Carolina Eyecare Physicians
CHARLESTON, S.C.–(BUSINESS WIRE)–Belle Hall Eye Care and Eyecare Specialties of Charleston, two Charleston-based optometric practices, have partnered with US EYE and Carolina Eyecare Physicians to enrich patient care and expand the group’s multi-disc…
Desktop Health Adds PhonoGraft Biofabrication Platform to Growing Technology Portfolio
NEWPORT BEACH, Calif.–(BUSINESS WIRE)– #3DP–Desktop Health to develop PhonoGraft technology, a 3D printed biofabrication solution that offers a promising pathway for soft tissue regeneration.
Polpharma Biologics Group Announces That Its Joint Venture Company, Bioeq, Has Entered Into a Commercialization Agreement for Biosimilar Ranibizumab
WARSAW, Poland–(BUSINESS WIRE)– #biologics–Polpharma Biologics Group announces that its joint venture company, Bioeq, has entered into a commercialization agreement for biosimilar Ranibizumab.
Now Delivered in a Bottle, Oasis TEARS® PF PLUS Preservative-Free Lubricant Eye Drops for the Relief of Dry Eye Symptoms
GLENDORA, Calif.–(BUSINESS WIRE)– #oasistears–OASIS® Medical Inc., manufacturer and distributor of SOFT PLUG® brand of punctal plugs and Oasis TEARS® Preservative-Free Lubricating Eye Drops is formally launching Oasis TEARS® PF PLUS preservative-fre…
jCyte Announces Appointment of Adrian Morris as Chief Development Officer
NEWPORT BEACH, Calif.–(BUSINESS WIRE)–jCyte, Inc., a private biotechnology company dedicated to improving the lives of patients with retinal degenerative diseases, announced the continued expansion of the company’s executive management team with the …
Eyewear and Optical Retailers Database for Europe 2021 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Eyewear and Optical Retailers in Europe” newsletter has been added to ResearchAndMarkets.com’s offering. For each country, similar rankings are provided covering all the major optical retailers. This database covers all ma…
Iveric Bio Receives FDA Agreement Under Special Protocol Assessment (SPA) for GATHER2 Phase 3 Clinical Trial of Zimura® in Geographic Atrophy Secondary to Age-Related Macular Degeneration
NEW YORK–(BUSINESS WIRE)–Iveric Bio announced that the Company received written agreement from the US FDA under a Special Protocol Assessment (SPA) for the design of GATHER2.
Glaucoma Research – Global Clinical Trials Review, H1, 2021 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Glaucoma – Global Clinical Trials Review, H1, 2021” clinical trials has been added to ResearchAndMarkets.com’s offering. This report presents top line data relating to the clinical trials on Glaucoma. Report includes an ov…
Worldwide Eye Care Industry to 2026 – Growing Prevalence of Different Ocular Problems is Driving Growth – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Eye Care Market, By Product Type (Eyeglasses, Eye Drops, Contact Lens, Intraocular Lens, Eye Vitamins, Others), By Eye Drops (Prescription v/s Over-The-Counter), By Coating, By Lens Material, By Distribution Channel…
Aldeyra Therapeutics Joins the Russell 2000® and Russell 3000® Indexes
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases, today announced that the company was added to the broad-…
Global Vision Care Market (2021 to 2026) – Industry Trends, Share, Size, Growth, Opportunity and Forecasts – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Vision Care Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026” report has been added to ResearchAndMarkets.com’s offering. The global vision care market reached a value of US$ 63.1 Bil…
VerkaziaMC (cyclosporine à 0,1 %) est désormais couvert par le régime public du Nouveau-Brunswick pour traiter la kératoconjonctivite vernale grave
TORONTO–(BUSINESS WIRE)–Verkazia Reimbursement for New Brunswick
Verkazia™ (cyclosporine 0.1%) for the Treatment of Severe Vernal Keratoconjunctivitis is now Publicly Reimbursed in New Brunswick
TORONTO–(BUSINESS WIRE)–Verkazia Reimbursement for New Brunswick
Deep 6 AI Announces Substantial Expansion of its Innovative AI-Based Clinical Trial Acceleration Software and Research Ecosystem
PASADENA, Calif.–(BUSINESS WIRE)–Deep 6 AI, the leader in artificial intelligence (AI)-based clinical trial acceleration software (CTAS), today announced significant growth.
Aurion Biotech Names Edward Holland, MD, Chief Medical Advisor
SEATTLE & BOSTON & TOKYO–(BUSINESS WIRE)–Aurion Biotech has appointed Edward Holland, MD, as Chief Medical Advisor.
Ocular Therapeutix™ and Mosaic Biosciences Enter into Strategic Discovery Collaboration Targeting the Treatment of Dry Age-Related Macular Degeneration
BEDFORD, Mass.–(BUSINESS WIRE)—- $OCUL #OCUTX–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, entered…
Adaptive Phage Therapeutics Expands Board Following Series B Financing Led by Deerfield Management
GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics Expands Board Following Series B Financing Led by Deerfield Management
Enspryng (Satralizumab) von Chugai, von der Europäischen Kommission als erste subkutane Behandlung für zu Hause bei Neuromyelitis-optica-Spektrum-Erkrankungen (NMOSD) zugelassen
TOKIO, Japan–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) gab heute bekannt, dass Roche von der Europäischen Kommission die Marktzulassung für den pH-abhängig bindenden humanisierten monoklonalen Anti-IL-6-Rezeptor-Antikörper Enspryn…
歐盟委員會核准中外製藥的Enspryng (Satralizumab)作為首款用於治療泛視神經脊髓炎(NMOSD)的居家皮下治療藥物
東京–(BUSINESS WIRE)–(美國商業資訊)–中外製藥株式會社(Chugai Pharmaceutical Co., Ltd., TOKYO:4519)今天宣布，歐盟委員會已向羅氏(Roche)簽發市售授權，核准中外製藥研製的pH依賴型結合人源化抗IL-6受體單株抗體Enspryng® (satralizumab)，將其作為抗水通道蛋白-4抗體(AQP4-IgG)血清陽性的成人及12歲以上青少年泛視神經脊髓炎(NMOSD)患者的首個皮下治療選擇，作為單藥治療或聯合免疫抑制治療(IST…